MARKET

HRTX

HRTX

Heron Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.89
-0.85
-7.24%
After Hours: 10.89 0 0.00% 16:59 04/01 EDT
OPEN
11.43
PREV CLOSE
11.74
HIGH
11.62
LOW
10.87
VOLUME
744.97K
TURNOVER
--
52 WEEK HIGH
26.81
52 WEEK LOW
9.60
MARKET CAP
984.18M
P/E (TTM)
-4.3482
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average HRTX stock price target is 39.78 with a high estimate of 65.00 and a low estimate of 28.00.

EPS

HRTX News

More
  • FDA accepts Innocoll application for post-surgical pain implant
  • seekingalpha · 6d ago
  • Key events next week - healthcare
  • Seeking Alpha - Article · 03/20 15:23
  • Will COVID-19 Derail New Drugs?
  • MotleyFool.com · 03/18 11:30
  • The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
  • Benzinga · 03/12 11:37

Industry

Biotechnology & Medical Research
-4.52%
Pharmaceuticals & Medical Research
-2.91%

Hot Stocks

Symbol
Price
%Change

About HRTX

Heron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company's product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company's SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). HTX-019, which is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, is being developed for the prevention of CINV. HTX-011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. HTX-011 is in Phase II clinical trials.
More

Webull offers kinds of Heron Therapeutics Inc stock information, including NASDAQ:HRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HRTX stock news, and many more online research tools to help you make informed decisions.